Core Insights - Biotalys has made significant progress in its mission to bring sustainable precision biocontrols to market, particularly with its first biocontrol candidate, EVOCA, which is advancing through the regulatory approval process in the U.S. and Europe [2][4][7] - The company has established a strategic partnership with AgroFresh to develop post-harvest biobased solutions, addressing challenges in the supply chain for fresh produce [3][5][10] - Financial results for the first half of 2025 show an operating loss of €8.1 million, with cash and cash equivalents at €15.7 million, providing a financial runway into May 2026 [9][6][18] Regulatory Developments - Biotalys is collaborating closely with the EPA in the U.S. and the CTGB in Europe to expedite the regulatory review of EVOCA, with expectations for final steps in the registration process by Q4 2025 [4][7] - Positive evaluations from the CTGB and RIVM have paved the way for the peer review phase in Europe, with no critical concerns identified regarding EVOCA's active ingredient [7] Research and Development Updates - Research and development expenses increased to €6.5 million in H1 2025, primarily due to higher external costs, while net cash used in operations was €6.1 million, slightly lower than the previous year [11][18] - Biotalys is advancing its pipeline with multiple programs, including BioFun-6, which has shown strong efficacy in trials, and is collaborating with various academic and industry partners to further develop its product candidates [10][19] Corporate Highlights - The leadership team has been expanded with experienced executives, including the appointment of a new Chief Financial Officer and a new board member with extensive industry experience [10] - Biotalys has strengthened its patent position, obtaining patent protection for EVOCA in Brazil and China, and has been recognized in the FoodTech 500 list, ranking 32 [10][19]